Most new investors won't touch a penny stock and will likely think that the Leronlimab story is too good to be true and won't think twice about it. Until we have undisputable evidence that Leronlimab is a long term low risk investment, institutions won't risk their livelihood on it. We are not that far away from reaching the point where reward far outweighs risk. Very soon...